Press Release
Arcadia Biosciences (RKDA) Announces First-Quarter 2021 Financial Results and Business Highlights
"With our acquisition of select assets of
Recent Operating and Business Highlights
- Arcadia Acquires Portfolio of CBD Wellness Brands from
The Parent Company . Arcadia announced today that it has acquired select assets of Lief and Zola, including their portfolio of wellness brands fromThe Parent Company . The acquisition includes leading consumer brands likeSoul Spring TM, the top selling CBD-infused botanical therapy brand in the natural category, Saavy NaturalsTM, a leading line of all-natural body care products, Zola®, a leading coconut water sourced exclusively with sustainably grown coconuts fromThailand , and ProvaultTM, a CBD-infused sports performance formula providing effective support and recovery for athletes. As part of the transaction, Arcadia gains access to distribution channels and relationships in more than 5,000 stores nationally, the Lief manufacturing operations, which occupy a 20,000 square foot, GMP-licensed, ISO-certified manufacturing facility, as well as an experienced senior management team who brings years of expertise and success in the fast-moving consumer goods industry. - Belinda Yao Joins Arcadia as Vice President of Operations. Arcadia recently announced the hiring of
Belinda Yao as VP of operations to oversee supply chain manufacturing for the company, including demand planning, procurement and supplier relationships, order fulfillment, inventory management, logistics, customer service and data analytics. Yao is a former supply chain lead forThe Dannon Company , Harmless Harvest and Live Zola, and she will expand Arcadia's ability to drive direct-to-consumer sales for GoodWheat, GoodHemp™ and SONOVA® GLA safflower oil products, as well as the newly acquired portfolio of wellness products. - Arcadia Acquires European Food Ingredient Platform, Enhancing GoodWheat Business and Broadening Market Access in
Europe . InApril 2021 , throughArcadia SPA, S.L ., Arcadia acquired the assets of Agrasys S.A, a food ingredients company based inBarcelona, Spain . The transaction includes the physical and intellectual property assets to commercialize Tritordeum, a proprietary combination of durum wheat and wild barley, resulting in a nutritious cereal grain that is high in fiber, protein and antioxidants. Agrasys' network includes more than 50 grain producers and 25 millers and distributors, commercializing Tritordeum in 10 countries with seven retailers inEurope , most recently launching withAlbert Heijn , the largest grocery retailer inHolland . - Health Canada Approves GoodHemp Seed Varieties, Enabling Sales in
Canada . Also in April, Arcadia announced that three of its GoodHemp™ varieties – Rogue, Umpqua and Santiam – earned approval fromHealth Canada for their consistency and compliance. The approval is the final step to enable hemp seed sales inCanada . GoodHemp seed varieties and genetics are distributed inCanada by Tritium 3H, Inc. (T3H), which specializes in hemp field testing, certified seed production, commercialization and distribution of industrial hemp varieties. The approval fromHealth Canada broadens the geographic opportunities for GoodHemp and enables growers to access high quality seeds through Tritium for the 2021 growing season. - GoodHemp Seed Varieties Earn AOSCA Certification. Arcadia announced in February that four of its GoodHemp varieties – Rogue, Umpqua, Santiam and Potomac – have all passed the rigorous standards of the national
Association of Official Seed Certifying Agencies (AOSCA) variety review board. The variety review is conducted by representatives of seed certifying agencies, academia, the seed industry andUSDA to make certain new varieties are distinct, uniform and stable. AOSCA certification signifies to the industry that GoodHemp seed is produced to the highest standards for genetic purity, uniformity, high germination and feminization rates and varietal identity. It also enables sales in states such asFlorida , that require AOSCA certified hemp seed for planting. - Leading Consumer Food Industry Executive Joins Board.
Debbie Carosella , a prominent consumer food industry executive, joined Arcadia's board of Directors inFebruary 2021 . Carosella is the former CEO of Madhava Natural Sweeteners, a company that provides natural alternatives to refined sugars and artificial sweeteners. A recognized leader in the natural and organic food industry, she previously served as the senior vice president of innovation forDean Foods/ WhiteWave Foods where she led the development of value-added brands across the company. Prior to that, Carosella was on the executive leadership team atConAgra Foods where she was both a general manager and innovator for numerous brands in a multitude of food categories. $25.1 Million Private Placement Priced At the Market. InJanuary 2021 , Arcadia closed a private placement priced at-the-market with gross proceeds of$25.1 million . The funds will be used for general corporate purposes, including building Arcadia's global GoodWheat family of consumer brands, development of its e-commerce, direct-to-consumer digital marketing infrastructure to launch branded pasta, flour and other products, and to fund its Archipelago Ventures Hawaiian hemp cultivation and mainland CBD extraction operations.- E-commerce and Retail Platforms Established for GoodWheat Pasta and Flour. Arcadia entered 2021 with a functioning e-commerce website, and an SEO and digital media marketing plan to begin the design, test, and prove cycles needed to confirm its e-commerce scale-up strategy. The company began that effort in mid-February of this year. Initial results were very favorable in driving traffic to the site, but initially, with sub-par sales conversion. Modifications were made to the SEO formulas and the company recently saw much better conversion rates. Arcadia will continue its optimization efforts and expects to substantially increase ad spend later in the year to drive increased sales volumes.
|
|||||||
Financial Snapshot |
|||||||
(Unaudited) |
|||||||
($ in thousands) |
|||||||
Three Months Ended |
|||||||
2021 |
2020 |
Favorable / (Unfavorable) |
|||||
$ |
% |
||||||
Total Revenues |
828 |
309 |
519 |
168% |
|||
Total Operating Expenses |
6,154 |
6,099 |
(55) |
(1)% |
|||
Loss From Operations |
(5,326) |
(5,790) |
464 |
8% |
|||
Net Income Attributable to |
2,058 |
2,525 |
(467) |
(19)% |
Revenues
In the first quarter of 2021, revenues were
Operating Expenses
In the first quarter of 2021, operating expenses were
Net Income Attributable to Common Stockholders
Net income attributable to common stockholders for the first quarter of 2021 was
Conference Call and Webcast
The company has scheduled a conference call for
Interested participants can join the conference call using the following numbers:
International Dial-In: +1-225-283-0138
Passcode: 7782155
A live webcast of the conference call will be available on the "Investors" section of the Arcadia website at www.arcadiabio.com. Following completion of the call, a recorded replay will be available on the company's investor website.
About
Safe Harbor Statement
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release and the accompanying conference call contain forward-looking statements about the company and its products, including statements relating to projected revenue growth as a result of the asset acquisition. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the price and demand for the company's products are lower than expected; the company's and its partners' and affiliates' ability to develop and sell commercial products incorporating its traits, and complete the regulatory review process for such products; the company's compliance with laws and regulations that impact the company's business, including the sale of products containing CBD and changes to such laws and regulations; the growth of the global wheat and hemp markets; the successful integration of the acquired brands and assets into Arcadia's business; the potential impact of COVID-19 on the company's business; and the company's future capital requirements and ability to satisfy its capital needs. Further information regarding these and other factors that could affect the company's financial results is included in filings the company makes with the
|
|||
Condensed Consolidated Balance Sheets |
|||
(Unaudited) |
|||
(In thousands, except share data) |
|||
|
|
||
Assets |
|||
Current assets: |
|||
Cash and cash equivalents |
32,848 |
|
|
Short-term investments |
19,088 |
11,625 |
|
Accounts receivable |
1,113 |
1,406 |
|
Inventories, net — current |
2,663 |
3,812 |
|
Prepaid expenses and other current assets |
901 |
811 |
|
Total current assets |
56,613 |
31,696 |
|
Restricted cash |
- |
2,001 |
|
Property and equipment, net |
3,480 |
3,539 |
|
Right of use asset |
5,636 |
5,826 |
|
Inventories, net — noncurrent |
4,290 |
3,485 |
|
|
408 |
408 |
|
Intangible assets, net |
350 |
370 |
|
Other noncurrent assets |
23 |
23 |
|
Total assets |
$ 70,800 |
$ 47,348 |
|
Liabilities and stockholders' equity |
|||
Current liabilities: |
|||
Accounts payable and accrued expenses |
$ 3,418 |
$ 4,105 |
|
Amounts due to related parties |
26 |
80 |
|
Debt — current |
1,141 |
1,141 |
|
Unearned revenue — current |
63 |
8 |
|
Operating lease liability — current |
705 |
717 |
|
Other current liabilities |
264 |
263 |
|
Total current liabilities |
5,617 |
6,314 |
|
Debt — noncurrent |
96 |
2,105 |
|
Operating lease liability — noncurrent |
5,228 |
5,389 |
|
Common stock warrant liabilities |
12,016 |
2,708 |
|
Other noncurrent liabilities |
2,140 |
2,280 |
|
Total liabilities |
25,097 |
18,796 |
|
Stockholders' equity: |
|||
Common stock, 21,336,249 and 13,450,861 shares issued and outstanding as of |
62 |
54 |
|
Additional paid-in capital |
254,208 |
239,496 |
|
Accumulated deficit |
(209,767) |
(211,825) |
|
Total |
44,503 |
27,725 |
|
Non-controlling interest |
1,200 |
827 |
|
Total stockholders' equity |
45,703 |
28,552 |
|
Total liabilities and stockholders' equity |
$ 70,800 |
$ 47,348 |
|
|||
Condensed Consolidated Statements of Operations and Comprehensive Income |
|||
(Unaudited) |
|||
(In thousands, except share and per share data) |
|||
Three Months Ended |
|||
2021 |
2020 |
||
Revenues: |
|||
Product |
$ 803 |
$ 154 |
|
License |
- |
100 |
|
Royalty |
25 |
30 |
|
Contract research and government grants |
— |
25 |
|
Total revenues |
828 |
309 |
|
Operating expenses: |
|||
Cost of product revenues |
856 |
132 |
|
Research and development |
1,159 |
2.244 |
|
Change in fair value of contingent consideration |
(140) |
— |
|
Write-down of fixed assets |
210 |
— |
|
Selling, general and administrative |
4,069 |
3,723 |
|
Total operating expenses |
6,154 |
6,099 |
|
Loss from operations |
(5,326) |
(5,790) |
|
Interest expense |
(9) |
(3) |
|
Other income, net |
7,463 |
72 |
|
Issuance and offering costs |
(769) |
— |
|
Change in fair value of common stock warrant liabilities |
322 |
8,161 |
|
Net income before income taxes |
1,681 |
2,440 |
|
Income tax provision |
— |
(17) |
|
Net income |
1,681 |
2,423 |
|
Net loss attributable to non-controlling interest |
(377) |
(102) |
|
Net income attributable to common stockholders |
$ 2,058 |
$ 2,525 |
|
Net income per share attributable to common stockholders: |
|||
Basic |
$ 0.11 |
$ 0.29 |
|
Diluted |
$ 0.11 |
$ 0.29 |
|
Weighted-average number of shares used in per share calculations: |
|||
Basic |
18,970,250 |
8,651,213 |
|
Diluted |
19,042,962 |
8,674,610 |
|
Other comprehensive loss, net of tax |
|||
Unrealized losses on investment securities |
— |
(1) |
|
Other comprehensive loss |
— |
(1) |
|
Comprehensive income attributable to common stockholders |
$ 2,058 |
$ 2,524 |
|
|||
Condensed Consolidated Statements of Cash Flows |
|||
(Unaudited) |
|||
(In thousands) |
|||
Three Months Ended |
|||
2021 |
2020 |
||
CASH FLOWS FROM OPERATING ACTIVITIES: |
|||
Net income |
$ 1,681 |
$ 2,423 |
|
Adjustments to reconcile net income to cash used in operating activities: |
|||
Change in fair value of common stock warrant liabilities |
(322) |
(8,161) |
|
Change in fair value of contingent consideration |
(140) |
— |
|
Issuance and offering costs |
769 |
— |
|
Depreciation |
236 |
74 |
|
Amortization of intangible assets |
20 |
— |
|
Lease amortization |
289 |
223 |
|
Net amortization of investment premium |
— |
(39) |
|
Stock-based compensation |
325 |
772 |
|
Unrealized gain on corporate securities |
(7,463) |
— |
|
Write-down of fixed assets |
210 |
— |
|
Write-down of inventory |
160 |
59 |
|
Changes in operating assets and liabilities: |
|||
Accounts receivable |
293 |
293 |
|
Inventories |
184 |
(4,145) |
|
Prepaid expenses and other current assets |
(90) |
(748) |
|
Other noncurrent assets |
— |
(15) |
|
Accounts payable and accrued expenses |
(591) |
227 |
|
Amounts due to related parties |
(54) |
(24) |
|
Unearned revenue |
55 |
(25) |
|
Other current liabilities |
3 |
— |
|
Operating lease payments |
(272) |
(184) |
|
Net cash used in operating activities |
(4,707)) |
(9,270) |
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|||
Purchases of property and equipment |
(485) |
(778) |
|
Purchases of investments |
— |
(1,292) |
|
Proceeds from sales and maturities of investments |
— |
15,200 |
|
Net cash (used in) provided by investing activities |
(485) |
13,130 |
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|||
Proceeds from issuance of common stock and warrants from |
25,147 |
— |
|
Payments of offering costs relating to securities purchase agreement |
(1,912) |
— |
|
Principal payments on debt |
(2,009) |
(7) |
|
Proceeds from ESPP purchases |
21 |
14 |
|
Capital contributions received from non-controlling interest |
750 |
689 |
|
Net cash provided by financing activities |
21,997 |
696 |
|
Net increase in cash, cash equivalents and restricted cash |
16,805 |
4,556 |
|
Cash, cash equivalents and restricted cash — beginning of period |
16,043 |
8,417 |
|
Cash, cash equivalents and restricted cash — end of period |
$ 32,848 |
$ 12,973 |
|
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
|||
Cash paid for income taxes |
$ — |
$ 2 |
|
Cash paid for interest |
$ 19 |
$ 3 |
|
NONCASH INVESTING AND FINANCING ACTIVITIES: |
|||
Fixed assets acquired with notes payable |
$ — |
$ 37 |
|
Common stock warrants issued to placement agent and included in offering costs related to |
$ 942 |
$ — |
|
Right of use assets obtained in exchange for new operating lease liabilities |
$ — |
$ 3,836 |
|
Purchases of fixed assets included in accounts payable and accrued expenses |
$ 25 |
$ — |
View original content to download multimedia:http://www.prnewswire.com/news-releases/arcadia-biosciences-rkda-announces-first-quarter-2021-financial-results-and-business-highlights-301292895.html
SOURCE
Arcadia Biosciences Contact: Pam Haley, Chief Financial Officer, ir@arcadiabio.com